In bladder cancer, it was found that m6A RNA methylation regulators could participate in the malignant progression of bladder cancer, and a risk signature with three selected m6A RNA methylation regulators (FTO, YTHDC1, and WTAP) could serve as a promising prognostic biomarker [8]. This evidence concerns the gene YTHDC1 and urinary bladder cancer.